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Ever since its discovery in 1953 by N. O. Kaplan and coworkers, the physiological role of the proton-translocating transhydrogenase has
generally been assumed to be that of generating mitochondrial NADPH. Mitochondrial NADPH can be used in a number of important reactions/
processes, e.g., biosynthesis, maintenance of GSH, apoptosis, aging etc. This assumed role has found some support in bacteria but not in higher
eukaryotes, a situation which changed dramatically with two recent but separate findings, both using transhydrogenase knockouts, in the nematode
C. elegans and the mouse strain C57BL/6J. The latter, which is due to a spontaneous deletion mutation in the Nnt gene, was serendipitously found
during investigations of the diabetic properties of these mice. The implications of these findings for the overall role of transhydrogenase in cell
metabolism and disease are discussed.
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The mitochondrion is one of the major cellular sources of
reactive oxygen species (ROS), generated mainly in Complexes
I and III [1]. Electron leakage during respiration leads to the
generation of superoxide anions and oxidative stress, defined as
a disturbance in the prooxidant–antioxidant balance in favour of
the former [1,2]. Mitochondrial ROS-mediated cell damage has
been implicated in aging, apoptosis, necrosis and a number of
pathological changes, including neurodegenerative diseases and
cancer, mediated by, e.g., Ca2+ fluxes, apoptotic proteins, poly
(ADP-ribose)polymerase (PARP) and mitochondrial channels
[2–8]. The primary defenses against mitochondrially generated
ROS are superoxide dismutases, such as mitochondrial MnSOD
[9] and glutathione peroxidase [10]. Reduced glutathione
(GSH) participates in the defense against ROS and repair of
mitochondrial oxidative damage both as a potent antioxidant in
itself and as a substrate for mitochondrial glutathione pero-
xidase and glutathione-dependent phospholipid hydroperoxi-
dase [10,11]. Since ROS may diffuse to the cytosol, cytosolic
glutathione peroxidase may also be involved in the conversion⁎ Tel.: +46 31 7733921; fax: +46 31 7733911.
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doi:10.1016/j.bbabio.2006.03.010to non-toxic metabolites [10, 11]. Mitochondrial and cytoplas-
mic pools of glutathione are separate [12] and GSH levels in
these pools are maintained by their respective NADPH-
dependent glutathione reductases [13]. For example, the clas-
sical initiation of apoptosis by tert-butylhydroperoxide [3] is
mediated by oxidation of mitochondrial GSH and NAD(P)H
[14].
2. Sources of mitochondrial NADPH
A significant contributor to mitochondrial NADPH is
the proton-translocating transhydrogenase that catalyzes the
reaction
Hþout þ NADHþ NADPþ W Hþin þ NADþ þ NADPH ð1Þ
(for reviews on the properties of transhydrogenase, see Refs.
[15,16]). In the presence of an electrochemical proton gradient,
Δp, i.e., under physiological conditions, the reaction is strongly
shifted towards NADPH formation and the rate of the reaction
from left to right is enhanced 5- to 10-fold. The redox level of
mitochondrial NADP is normally more than 95% reduced, about
half of which is uncoupler sensitive [17]. Thus, the uncoupler-
sensitive part is consistent with transhydrogenase-generated
NADPH, even though contributions by other sources, e.g., the
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from a flux investigation of redox equivalents in E. coli under
different conditions, transhydrogenase accounts for up to 45% of
the NADPH flow, the remaining contributed mainly by the
pentose phosphate pathway, NADP-isocitrate dehydrogenase
and decarboxylating malate dehydrogenase (malic enzyme)
[18]. In mitochondria, the contribution of NADPH by trans-
hydrogenasemay thus be assumed to be at least as high or higher.
It should also be stressed that transhydrogenase, at the high
NADPH/NADP+ redox ratio prevailing in mitochondria, has
been proposed to be largely product inhibited [19], i.e., its ma-
ximal activity, approx. 30 nmol/min/mg mitochondrial protein,
is only reached upon a consumption of the product NADPH at a
rate exceeding that of the steady-state rate of transhydrogenase.
3. Proposed roles of transhydrogenase
As mentioned above, mitochondrial peroxides are reduced
by GSH and glutathione peroxidase, and the GSSG formed is
assumed to be reduced primarily by NADPH generated by
transhydrogenase. By estimating oxidative damage as release
of Ca2+, mitochondria generating NADPH by the addition
of a NADH-linked substrate are therefore less sensitive to
tert-butylhydroperoxide than mitochondria provided with a
NADPH-linked substrate [14]. Initially, this seemed confusing
but is, in fact, consistent with the properties of the transhy-
drogenase reaction. Because of the linkage toΔp, the reaction is
able to generate a high NADPH/NADP+ ratio at a relatively low
rate, in contrast to, e.g., the NADP-isocitrate dehydrogenase
reaction which generates a lower NADPH/NADP+ ratio but at a
higher maximal rate. The experiment with tert-butylhydroper-
oxide therefore allows the important conclusion that protection
against mitochondrial oxidative stress depends on the redox
level of NADP(H), i.e., NADPH/NADP+, and thus GSG/
GSSG, rather than the capacity for NADPH generation.
Replenishment of GSH in brain mitochondria involves transhy-
drogenase [20], and transhydrogenase also enables Rhodobacter
sphaeroides to metabolize methanol through a GSH-linked
degradation system [21]. As will be described in more detail in
the following chapter, transhydrogenase protects C. elegans
nematodes against ROS through the generation of GSH. Thus, it
may be generally concluded that an important function of
transhydrogenase is to maintain a high GSH/GSSG ratio.
Other proposed roles include a regulation of NADPH-
dependent protein thiols [19], and thereby activities of, e.g.,
crucial membrane proteins such as the mitochondrial perme-
ability transition pore (MPTP) [22]. By reversing reaction [1],
another role of transhydrogenase would be to generate a short
burst of a proton motive force (Δp) under anaerobic/ischemic
conditions. However, since ΔG0 for the nucleotide substrates/
products of reaction [1] is close to zero, this burst would be very
short considering that the total free energy available is in the
form of a high product/substrate ratio and equilibration would be
expected to be fast. A significant contribution of the reverse
reaction to Δp would therefore be insignificant. It was early
proposed that mitochondrial NADPH, under conditions of an
increased demand for cytosolic NADPH, transhydrogenase-generated NADPH could contribute to the synthesis of isocitrate
through the reversible NADP-isocitrate dehydrogenase, fol-
lowed by transport of isocitrate/citrate to the cytosol by the
tricarboxylate carrier and a reversal of the analogues cytosolic
NADP-isocitrate dehydrogenase system [19]. Subsequently,
Jackson and coworkers [23] suggested that transhydrogenase,
together with the NAD- and NADP-isocitrate dehydrogenases,
would regulate the Krebs cycle by forming a Δp-consuming
futile cycle. Although potentially very attractive, there is no
experimental support for this mechanism. On the contrary, a
specific inhibitor of the NADP-isocitrate dehydrogenase affects
the NADPH level in a manner inconsistent with the proposal
[23]. In addition, as pointed out in the proposal, this mechanism
of course requires a coexistence of transhydrogenase and
NADP-isocitrate dehydrogenase, which seems to be true for
mitochondria from different sources [24] but not yeasts which
generally do not have transhydrogenase but do have NADP-
isocitrate dehydrogenase [25]. Obviously, an interaction bet-
ween the NADP-isocitrate dehydrogenase and transhydrogenase
appears inevitable, but the relevance and extent of this inter-
action for the regulation of the Krebs cycle in the intact cell
remains to be demonstrated.
Transhydrogenase activities of E. coli and other enteric
bacteria are apparently co-regulated with glutamate dehydroge-
nase, and can vary several-fold depending on, e.g., the source of
ammonia; it was proposed that transhydrogenase is a direct
source of NADPH in the ammonia assimilation system [26].
Also, growth on branched amino acids, e.g., leucine, suppresses
transhydrogenase [27]. Transhydrogenase (Pnt) knock-outs inE.
coli show a phenotype with limited growth in the absence of the
pentose phosphate pathway, but otherwise no apparent pheno-
types [28–30]. E. coli has a separate, soluble transhydrogenase
(UdhA), co-existing with the membrane-bound enzyme (Pnt),
which seems to be working during excess NADPH production
[18]. However, the existence of UdhA seems to be restricted to
E. coli and possibly other bacteria, and has not been found in
mitochondria.
The relevance of the functions and regulation of transhy-
drogenase in bacteria for the mitochondrial enzyme is presently
unknown. However, it is conceivable that the role of trans-
hydrogenase varies with the organism in which it is located.
Fig. 1 outlines transhydrogenase with an emphasis on its role
as a redox buffer and thus a redox regulator of glutathione,
protein thiols and other thiol systems, notably mitochondrial
thioredoxin (Trx2) and glutaredoxin (Grx2). Both of the latter
are maintained reduced by the mitochondrial Trx-reductase
(TrxR); Trx2 and Grx2 have important roles in the regulation
and protection of protein thiols [31]. Oxidized mitochondrial
phospholipids are reduced by glutathione peroxidase including
the mitochondrial phospholipid hydroperoxidase (HGPx) [11].
4. Properties of a C. elegans transhydrogenase deletion
mutant
Transhydrogenase in C. elegans, denoted NNT, is globally
expressed [32], with a particularly high expression in the pha-
ryngeal–intestinal valve and certain neurons. In the mouse, high
Fig. 2. Generation of toxic organic peroxides by Paraquat in C. elegans
mitochondria, and the detoxification mechanism involving transhydrogenase.
NNT (in red), transhydrogenase; MV, methylviologen or Paraquat; SOD,
superoxide dismutase; GPx, glutathione peroxidase; PHGPx, phospholipid
hydroperoxidase. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Fig. 1. Role of transhydrogenase in the maintenance of the mitochondrial NADPH and thiol redox homeostasis. Trx and Grx denote mitochondrial thioredoxin (Trx2)
and glutaredoxin (Grx2), respectively.
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and brain [32]. In order to further identify the physiological role
of transhydrogenase in C. elegans, a deletion mutation, nnt-1
(sv34), was constructed which was lacking essential parts of the
transhydrogenase gene, resulting in a phenotype devoid of
transhydrogenase protein as indicated by Western blots follow-
ing SDS-PAGE [33]. These nematodes showed essentially a
normal life span and other properties typical of wildtype nema-
todes living in a normal environment. However, analysis of the
cellular glutathione redox level, i.e., the GSH/GSSG ratio, which
in wildtype was approximately 60, dropped to 12 in the mutant
[33]. Due to the fact that the mitochondrial pool of glutathione is
approximately 10–15% of the total pool, this drop in GSH (and
increase in GSSG), was too large in order to only reflect a
mitochondrial stress. An “overflow” of mitochondrial oxidative
stress to the cytoplasm is therefore assumed [33]. Thus, it would
be expected that the mutant nematodes would be more sensitive
to especially mitochondrial oxidative stress than the wildtype
ones. Indeed, when exposed to 0.1–0.4 mM methylviologen
(Paraquat), a known redox cycler generating superoxide anions
primarily in mitochondria, eggs of the mutant nematode were
considerably more sensitive to mitochondrial oxidative stress
than wildtype eggs, assayed as growth to adult nematodes. The
defense against oxidative stress could be rescued by reintrodu-
cing the nnt-1 gene. Similar effects were seen with eggs treated
with siRNA.
Fig. 2 describes the mechanism of protection by transhy-
drogenase of C. elegans against methylviologen-dependent
oxidative stress. Through a high GSH/GSSG ratio, transhy-
drogenase-generated NADPH contributes to a detoxification of
peroxides formed from superoxide and lipid peroxidation.
This is the first time that a physiological role of transhy-
drogenase has been demonstrated in a higher eukaryote. The C.
elegans system, because of its simplicity, short generation time,
and established genome sequence, constitutes a very attractive
model system for further studies on, e.g., mechanisms of neu-ronal damage related to transhydrogenase and oxidative stress. A
further advantage with the nnt-1(sv34) mutant is that specific
mitochondrial mechanisms of ROS toxicity may be studied. In
this respect, the nnt-1(sv34) mutant resembles the mev-1 mutant
which generates excessive amounts of superoxide due to a
mutation in cytochrome b of Complex II [34].
5. Diabetes: a disease potentially inked to a defective
transhydrogenase gene
Oxidative stress, especially but not exclusively, mitochon-
drial oxidative stress, is believed to be involved in type 2
diabetes [35,36]. In the first demonstration ever of a linkage
between a disease and a defective transhydrogenase gene, Toye
et al. [37] showed that insulin release induced by high glucose
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mouse strains, e.g., C3H/HeH, DBA/2 and BALB/c. Thus, the
phenotype of the C57BL/6J mice was typical of a type 2 diabetes
condition, with an abnormal glucose tolerance. The defective
glucose tolerance was linked to a mutated Nnt gene in which a
multi-exon deletion was found, essentially resulting in a trans-
hydrogenase knock-out. The absence of transhydrogenase atte-
nuated the closure of the KATP channel in response to glucose
metabolism. Consequently, opening of the Ca2+-channel in theβ
cells was impaired, leading to an inhibition of insulin release.
The detailed mechanism leading to decreased insulin release is
discussed in more detail below.
In this context, it should be mentioned that Huang et al. [38]
discovered that DBA/2J mice containing a mutated Sod2 gene,
coding for the mitochondrial MnSOD, lived considerably longer
(8 days) as compared to the same mutation in C57BL/6J mice
(less than 24 h). As in the work by Toye et al. [37], C57BL/6J
mice were shown to essentially lack transhydrogenase protein.
The extended lifetime of the MnSOD-deficient DBA/2J mice
was therefore concluded to be due to the presence of trans-
hydrogenase. Thus, the absence ofMnSODwas compensated by
the presence of transhydrogenase.
The studies by Cox and coworkers of the role of trans-
hydrogenase in the regulation of insulin secretion have recently
been extended with, e.g., siRNA directed towards transhydro-
genase in an insulin-secreting cell line. Glucose-induced uptake
of Ca2+ wasmarkedly lowered by siRNA directed towards either
of the NAD(H)-binding or the NADP(H)-binding domains of
transhydrogenase, leading to a close to 100% lack of trans-
hydrogenase protein in the cells [39]. Endogenously generated
ROS in β cells isolated from wild-type and homozygous Nnt
G745D mutant mice was several-fold higher in the mutant mice
as compared to wild-type [39]. The G745D transhydrogenase
mutant is predicted to be inactive since glycine 745 is located in
the membrane domain of the enzyme (J. Rydström, unpub-Fig. 3. Proposed role of Nnt in ROS detoxification in β-cells. From Freeman et al. [
nucleotide translocator; NNT, transhydrogenase; SOD2, mitochondrial (Mn) superolished). Together, these results strongly suggest that the diabetic
characteristics of C57BL/6J mice are primarily due to an
impaired transhydrogenase activity. Indeed, these results also
strongly support the proposal of Arkblad et al. [33] that an
important role of transhydrogenase is to control ROS. In this
context, it should be pointed out that transhydrogenase is
strongly inhibited by fatty acyl CoA, especially long chain acyl
CoA [40], which may further suppress the transhydrogenase
activity in the presence of a high cellular content of fatty acids,
typical of a pre-diabetic condition [35].
The work byCox and coworkers [37,39] is remarkable and no
doubt a breakthrough in transhydrogenase research. Three im-
portant questions may be raised by these results: (i) Is the
C57BL/6j mice a model for human type 2 diabetes? (ii) What is
the mechanism of the decreased insulin release in C57BL/6J
mice? (iii) What other states/diseases may be visualized to be
caused by the lack of transhydrogenase?
The first question is really an epidemiological problem which
is presently investigated by others, but is beyond the scope of
this review.
The second question obviously involves one or more steps in
the mechanism of insulin release in β-cells. As described above,
the KATP channels are normally closed by a high cellular ATP/
ADP ratio generated by the metabolism of glucose and the
resulting synthesis of ATP. Closing of the KATP channel results in
a depolarization of the plasma membrane, activation of Ca2+-
channels, an increased cytosolic concentration of Ca2+, fusion of
insulin vesicles with the plasma membrane and release of free
insulin [37,41]. The key factor seems to be an increased level of
oxidative stress and a resulting decreased ATP/ADP ratio,
indirectly caused by the lack of transhydrogenase. An attractive
mechanism proposed by Cox and coworkers [39], involves
UCP2, a homologue of the H+-conducting uncoupler protein
UCP1 responsible for thermogenesis [42]. UCP2, and possible
also UCP3, is regulated by products of oxidative stress and lipid39] and reproduced with permission. UCP2, uncoupler protein 2; ANT, adenine
xide dismutase.
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alkenals [41]. These products bind to UCP2/UCP3, signalling
oxidative stress. Oxidative stress depends initially on one-
electron redox centers in the respiratory chain, primarily the
flavin in Complex I and semiquinone in Complex III, which
generate superoxide anions at rates determined by the redox
levels of the former centers [3]. The linkage between the res-
piratory chain and UCP2/UCP3 is that a slight uncoupling will
increase electron flow sufficiently for lowering the generation of
superoxide anions. Thus, in C57BL/6J mice, the absence of
transhydrogenase causes an increased basic level of oxidative
stress, a permanent partial uncoupling through UCP2/UCP3, a
decreased ATP/ADP ratio and permanently open KATP channels,
regardless of the presence of glucose, and therefore a lack of
insulin secretion. Being a proton-utilizing protein itself, a rele-
vant question is how transhydrogenase would affect the delicate
balance between ROS generation and proton flow across the
inner mitochondrial membrane. However, because of the low
ΔG0 value for the nucleotides, and despite consuming one
proton per catalytic turnover, the transhydrogenase reaction is
relative insensitive to changes in Δp. This is demonstrated by a
lower effect of a decreased Δp on reaction [1] under conditions
when oxidative phosphorylation is inhibited [43]. The relation-
ship between the two Δp-requiring reactions, where oxidative
phosphorylation may require up to 4 protons/ATP formed, can
also be expressed as a relatively small effect of reaction [1] on
oxidative phosphorylation. An overview of the mechanism
proposed by Freeman et al. [39] is shown in Fig. 3.
The third question may be answered by looking at the large
number of investigations that have been carried out and pub-
lished using C57BL/6J mice. However, this is not a straight
forward question since it is not known, of course, when the
mutation took place. Searching in PubMed for studies in which
C57BL/6J mice were used gives about 7000 hits, the majority of
which involves results from disease/toxicology-related investi-
gations. In the light of the present knowledge about the lack of
transhydrogenase in this strain, and the resulting increased level
of oxidative stress, it is likely that the results of some of these
studies have to be reinterpreted. However, inbred strains of
C57BL/6J mice show varying levels of transhydrogenase (N. B.
Pestov, personal communication), indicating different types of
genetic alterations in the transhydrogenase gene, and possibly
also in the promoter region.
6. Other diseases/conditions potentially involving
transhydrogenase
Apart from type 2 diabetes described above, and
possibly also type 1 diabetes, transhydrogenase may well
have a role in other diseases/conditions with a mitochon-
drial etiology [44–47]. Aging, e.g., longevity of C. elegans
nematodes, is strongly correlated with mitochondrial func-
tions [48], and is apparently also influenced by transhy-
drogenase in mice [38].
More specifically, there is a large body of evidence suggest-
ing that C57BL/6J mice have a much higher sensitivity to
neurotoxic agents, e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) which causes a Parkinson-like condition in
mice probably due to oxidative stress [49–51]. The effect of
MPTP was concluded to be related to a putative locus on chro-
mosome 13, where the transhydrogenase gene is located [52].
Unexpectedly, C57BL/6J mice show a lower cancer frequency
than, e.g., C3H/He and B6C3F1 mice, which was concluded to
be due to a lower growth rate of, e.g., liver tissue, rather than a
lower rate of apoptosis [53]. It is possible that the latter may be
triggered by a lower mitochondrial redox potential of NADP(H)
and/or a higher mitochondrial oxidative stress level. Finally,
there is an interesting potential linkage between alcohol-related
disease in the liver [54,55] heart involving mitochondrial glu-
tathione [56] and transhydrogenase.
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